Pseudorabies virus deletion mutants involving the EPO and LLT genes
US5352596A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Sep 11, 1992 |
| Grant date | Oct 4, 1994 |
| Priority date | — |
| Expiry date | Sep 11, 2012 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/948
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
An attenuated pseudorabies virus (PRV) having a reduced ability to reactivate from latency is produced by introducing (1) a genomic modification in the early protein 0 (EP0) gene whereby said virus is characterized by the inability to express the early protein 0; or (2) a genomic modification in the large latency transcript (LLT) gene whereby said virus is characterized by disruption of the synthesis of said large latency transcript; or (3) the genomic modifications described in both (1) and (2). The attenuated virus is useful in a vaccine for psuedorabies-susceptible animals, particularly swine. Swine vaccinated with a deletion mutant in the EP0/LLT overlap region displayed reduced virus shedding and fewer clinical signs than animals inoculated with a wild type virus. The deletion mutant-vaccinated swine also harbored less PRV DNA in the nervous tissue and showed reduced ability to reactivate the virus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.